Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 12/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962695 | 1.00 | ABL1 (0.38) | ABL1ALDH1A1GAAL3MBTL1GCK | |
| SCHEMBL4553930 | 0.91 | ALDH1A1 (0.40) | ABL1ALDH1A1GAAL3MBTL1GCK | |
| SCHEMBL4553929 | 0.91 | ALDH1A1 (0.40) | ABL1ALDH1A1GAAL3MBTL1GCK | |
| SCHEMBL966599 | 0.91 | ABL1 (0.37) | ABL1GCKPIM3SMN1; SMN2 | |
| SCHEMBL964065 | 0.89 | PIM3 (0.43) | ABL1ALDH1A1GAAL3MBTL1GCK | |
| SCHEMBL964067 | 0.89 | PIM3 (0.43) | ABL1ALDH1A1GAAL3MBTL1GCK | |
| SCHEMBL965630 | 0.87 | ALDH1A1 (0.40) | ALDH1A1GAAL3MBTL1HTR2AHTR2C | |
| SCHEMBL965631 | 0.87 | ALDH1A1 (0.40) | ALDH1A1GAAL3MBTL1HTR2AHTR2C | |
| SCHEMBL966513 | 0.87 | ALDH1A1 (0.44) | ALDH1A1GAAL3MBTL1NPC1RAB9A | |
| SCHEMBL966514 | 0.87 | ALDH1A1 (0.44) | ALDH1A1GAAL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | ABL1 3662/4885ALDH1A1 421/4885GAA 76/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | ABL1 4132/4885ALDH1A1 821/4885GAA 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.